This compound, OTS193320, attenuated γ-H2AX levels when used in combination with doxorubicin (DOX) compared with the DOX treatment alone, and caused a significant reduction in breast cancer cell viability when compared to the treatment with a single agent, OTS193320 or DOX. Here, H2AX is linked to breast carcinoma.